Points to consider in the development of national human genome editing policy.

Cambridge prisms, Precision medicine Pub Date : 2023-03-27 eCollection Date: 2023-01-01 DOI:10.1017/pcm.2023.11
Dianne Nicol, Simon Niemeyer, Rebecca Paxton, Christopher Rudge
{"title":"Points to consider in the development of national human genome editing policy.","authors":"Dianne Nicol, Simon Niemeyer, Rebecca Paxton, Christopher Rudge","doi":"10.1017/pcm.2023.11","DOIUrl":null,"url":null,"abstract":"<p><p>Clustered regularly interspaced short palindromic repeats and other genome editing technologies have the potential to transform the lives of people affected by genetic disorders for the better. However, it is widely recognised that they also raise large ethical and policy questions. The focus of this article is on how national genome editing policy might be developed in ways that give proper recognition to these big questions. The article first considers some of the regulatory challenges involved in dealing these big ethical and social questions, and also economic issues. It then reviews the outcomes of a series of major reports on genome editing from international expert bodies, with a particular focus on the work of the World Health Organization's expert committee on genome editing. The article then summarises five policy themes that have emerged from this review of the international reports together with a review of other literature, and the authors' engagement with members of the Australian public and with a wide range of experts across multiple disciplines. Each theme is accompanied by one to three pointers for policymakers to consider in developing genome editing policy.</p>","PeriodicalId":72491,"journal":{"name":"Cambridge prisms, Precision medicine","volume":" ","pages":"e23"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10953736/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cambridge prisms, Precision medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/pcm.2023.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Clustered regularly interspaced short palindromic repeats and other genome editing technologies have the potential to transform the lives of people affected by genetic disorders for the better. However, it is widely recognised that they also raise large ethical and policy questions. The focus of this article is on how national genome editing policy might be developed in ways that give proper recognition to these big questions. The article first considers some of the regulatory challenges involved in dealing these big ethical and social questions, and also economic issues. It then reviews the outcomes of a series of major reports on genome editing from international expert bodies, with a particular focus on the work of the World Health Organization's expert committee on genome editing. The article then summarises five policy themes that have emerged from this review of the international reports together with a review of other literature, and the authors' engagement with members of the Australian public and with a wide range of experts across multiple disciplines. Each theme is accompanied by one to three pointers for policymakers to consider in developing genome editing policy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在制定国家人类基因组编辑政策时应考虑的要点
定期间隔聚集的短回文重复序列和其他基因组编辑技术有可能使受遗传疾病影响的人的生活变得更好。然而,人们普遍认为,它们也引发了重大的伦理和政策问题。本文的重点是如何制定国家基因组编辑政策,以适当地认识到这些重大问题。本文首先考虑了在处理这些重大的伦理和社会问题以及经济问题时所涉及的一些监管挑战。然后,它审查了国际专家机构关于基因组编辑的一系列主要报告的结果,特别关注世界卫生组织基因组编辑专家委员会的工作。然后,文章总结了国际报告综述中出现的五个政策主题,以及对其他文献的综述,以及作者与澳大利亚公众成员和多学科广泛专家的接触。每个主题都伴随着一到三个指标,供决策者在制定基因组编辑政策时考虑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm. Cross-population applications of genomics to understand the risk of multifactorial traits involving inflammation and immunity. Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? Clinical translational research of liquid biopsy applications in prostate cancer and other urological cancers Heterogeneity in precision oncology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1